FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2108335853> ?p ?o ?g. }

• W2108335853 endingPage "1034.e1" @default.
• W2108335853 startingPage "1029" @default.
• W2108335853 abstract "There is uncertainty regarding the optimal adjunctive unfractionated heparin (UFH) regimen for percutaneous coronary intervention (PCI) in patients with non-ST-segment elevation acute coronary syndrome (NSTE-ACS) treated with fondaparinux.The aim of this study is to evaluate the safety of 2 dose regimens of adjunctive intravenous UFH during PCI in high-risk patients with NSTE-ACS initially treated with fondaparinux and referred for early coronary angiography.This is an international prospective cohort study of approximately 4,000 high-risk patients presenting to hospital with unstable angina or non-ST-segment elevation myocardial infarction, treated with fondaparinux as initial medical therapy, and referred for early coronary angiography with a view to revascularization. Within this cohort, 2,000 patients undergoing PCI will be eligible for enrollment into a double-blind international randomized parallel-group trial evaluating standard activated clotting time (ACT)-guided doses of intravenous UFH versus a non-ACT-guided weight-adjusted low dose. The standard regimen uses an 85-U/kg bolus of UFH if there is no platelet glycoprotein IIb/IIIa (GpIIb-IIIa) inhibitor or 60 U/kg if GpIIb-IIIa inhibitor use is planned, with additional bolus guided by blinded ACT measurements. The low-dose regimen uses a 50 U/kg UFH bolus, irrespective of planned GpIIb-IIIa use. The primary outcome is the composite of peri-PCI major bleeding, minor bleeding, or major vascular access site complications. The assessment of net clinical benefit is a key secondary outcome: it addresses the composite of peri-PCI major bleeding with death, myocardial infarction, or target vessel revascularization at day 30.FUTURA/OASIS 8 will help define the optimal UFH regimen as adjunct to PCI in high-risk NSTE-ACS patients treated with fondaparinux." @default.
• W2108335853 created "2016-06-24" @default.
• W2108335853 creator A5002031539 @default.
• W2108335853 creator A5003831287 @default.
• W2108335853 creator A5012215765 @default.
• W2108335853 creator A5014032885 @default.
• W2108335853 creator A5014449865 @default.
• W2108335853 creator A5018419311 @default.
• W2108335853 creator A5018963320 @default.
• W2108335853 creator A5047726859 @default.
• W2108335853 creator A5057167171 @default.
• W2108335853 creator A5057705555 @default.
• W2108335853 creator A5059093586 @default.
• W2108335853 creator A5089865834 @default.
• W2108335853 date "2010-12-01" @default.
• W2108335853 modified "2023-09-30" @default.
• W2108335853 title "Fondaparinux with UnfracTionated heparin dUring Revascularization in Acute coronary syndromes (FUTURA/OASIS 8): A randomized trial of intravenous unfractionated heparin during percutaneous coronary intervention in patients with non–ST-segment elevation acute coronary syndromes initially treated with fondaparinux" @default.
• W2108335853 cites W124721998 @default.
• W2108335853 cites W153597901 @default.
• W2108335853 cites W2010970163 @default.
• W2108335853 cites W2017231335 @default.
• W2108335853 cites W2060231998 @default.
• W2108335853 cites W2075209698 @default.
• W2108335853 cites W2087150869 @default.
• W2108335853 cites W2095901832 @default.
• W2108335853 cites W2109609988 @default.
• W2108335853 cites W2131370832 @default.
• W2108335853 cites W2141192690 @default.
• W2108335853 cites W2148907046 @default.
• W2108335853 cites W2157901674 @default.
• W2108335853 cites W2232858378 @default.
• W2108335853 cites W3162269940 @default.
• W2108335853 cites W4252057047 @default.
• W2108335853 cites W70145905 @default.
• W2108335853 doi "https://doi.org/10.1016/j.ahj.2010.07.037" @default.
• W2108335853 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21146654" @default.
• W2108335853 hasPublicationYear "2010" @default.
• W2108335853 type Work @default.
• W2108335853 sameAs 2108335853 @default.
• W2108335853 citedByCount "18" @default.
• W2108335853 countsByYear W21083358532012 @default.
• W2108335853 countsByYear W21083358532013 @default.
• W2108335853 countsByYear W21083358532014 @default.
• W2108335853 countsByYear W21083358532015 @default.
• W2108335853 countsByYear W21083358532017 @default.
• W2108335853 countsByYear W21083358532018 @default.
• W2108335853 countsByYear W21083358532019 @default.
• W2108335853 crossrefType "journal-article" @default.
• W2108335853 hasAuthorship W2108335853A5002031539 @default.
• W2108335853 hasAuthorship W2108335853A5003831287 @default.
• W2108335853 hasAuthorship W2108335853A5012215765 @default.
• W2108335853 hasAuthorship W2108335853A5014032885 @default.
• W2108335853 hasAuthorship W2108335853A5014449865 @default.
• W2108335853 hasAuthorship W2108335853A5018419311 @default.
• W2108335853 hasAuthorship W2108335853A5018963320 @default.
• W2108335853 hasAuthorship W2108335853A5047726859 @default.
• W2108335853 hasAuthorship W2108335853A5057167171 @default.
• W2108335853 hasAuthorship W2108335853A5057705555 @default.
• W2108335853 hasAuthorship W2108335853A5059093586 @default.
• W2108335853 hasAuthorship W2108335853A5089865834 @default.
• W2108335853 hasConcept C126322002 @default.
• W2108335853 hasConcept C141071460 @default.
• W2108335853 hasConcept C164705383 @default.
• W2108335853 hasConcept C2776291336 @default.
• W2108335853 hasConcept C2776877702 @default.
• W2108335853 hasConcept C2777557582 @default.
• W2108335853 hasConcept C2777698277 @default.
• W2108335853 hasConcept C2777785093 @default.
• W2108335853 hasConcept C2777987278 @default.
• W2108335853 hasConcept C2780400711 @default.
• W2108335853 hasConcept C2780868729 @default.
• W2108335853 hasConcept C2781413609 @default.
• W2108335853 hasConcept C2991741193 @default.
• W2108335853 hasConcept C45393284 @default.
• W2108335853 hasConcept C500558357 @default.
• W2108335853 hasConcept C71924100 @default.
• W2108335853 hasConceptScore W2108335853C126322002 @default.
• W2108335853 hasConceptScore W2108335853C141071460 @default.
• W2108335853 hasConceptScore W2108335853C164705383 @default.
• W2108335853 hasConceptScore W2108335853C2776291336 @default.
• W2108335853 hasConceptScore W2108335853C2776877702 @default.
• W2108335853 hasConceptScore W2108335853C2777557582 @default.
• W2108335853 hasConceptScore W2108335853C2777698277 @default.
• W2108335853 hasConceptScore W2108335853C2777785093 @default.
• W2108335853 hasConceptScore W2108335853C2777987278 @default.
• W2108335853 hasConceptScore W2108335853C2780400711 @default.
• W2108335853 hasConceptScore W2108335853C2780868729 @default.
• W2108335853 hasConceptScore W2108335853C2781413609 @default.
• W2108335853 hasConceptScore W2108335853C2991741193 @default.
• W2108335853 hasConceptScore W2108335853C45393284 @default.
• W2108335853 hasConceptScore W2108335853C500558357 @default.
• W2108335853 hasConceptScore W2108335853C71924100 @default.
• W2108335853 hasFunder F4320307773 @default.
• W2108335853 hasFunder F4320312415 @default.
• W2108335853 hasFunder F4320337529 @default.
• W2108335853 hasIssue "6" @default.
• W2108335853 hasLocation W21083358531 @default.
• W2108335853 hasLocation W21083358532 @default.

• next